Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-anti-CD103 Fab fragment
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-anti-CD103 Fab fragment (also known as [89Zr]Zr-hCD103.Fab01A) is a zirconium-89-labeled monoclonal antibody fragment (Fab) targeting CD103 (integrin alpha-E). CD103 is an integrin specifically expressed on the surface of cancer-reactive tumor-resident memory T cells (TRM), which significantly increases during successful immunotherapy. Developed by the University Medical Center Groningen, the University of Groningen, and Aduro Biotech, this radiopharmaceutical is designed as an immuno-PET imaging tracer to non-invasively assess cancer-reactive T cell infiltration and monitor response to cancer immunotherapy, particularly immune checkpoint inhibition.
- Other names
- 89Zr-anti-human CD103 Fab fragment89Zr-labeled anti-CD103 Fab fragmentzirconium-89-labeled anti-CD103 Fab fragmentzirconium89-labeled anti-CD103 Fab fragmentzirconium 89-labeled anti-CD103 Fab fragment
02
Targets
ITGAE (Integrin subunit alpha E)
Beyond the preview
Go deeper on 89Zr-anti-CD103 Fab fragment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-anti-CD103 Fab fragment.